跳转至内容
Merck
CN

E3638

Sigma-Aldrich

乙替唑仑溶液

别名:

8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

登录查看公司和协议定价

选择尺寸

关于此项目

线性分子式:
C16H11N4Cl
化学文摘社编号:
29975-16-4
分子量:
294.74
EC 号:
249-982-4
MDL编号:
MFCD00867537
UNSPSC代码:
12352200
PubChem化学物质编号:
24894524
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

200

药品控制

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

创始人

Abbott

SMILES字符串

Clc1ccc-2c(c1)C(=NCc3nncn-23)c4ccccc4

InChI

1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2

InChI key

CDCHDCWJMGXXRH-UHFFFAOYSA-N

基因信息

human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879)

正在寻找类似产品? 访问 产品对比指南

相关类别

生化/生理作用

Hypnotic; ligand for the GABAA receptor benzodiazepine modulatory site.

特点和优势

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H315,H319,H335

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
13170127
0000134210
0000134210
0000089034
128M4158V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Kirkwood, C.K., et al.
Journal of the American Pharmaceutical Association, 39, 688-688 (1999)
Chao-Yun Xia et al.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 29(3), 211-215 (2009-11-10)
To evaluate the therapeutic effects and safety of the XIA's No.1 Sleeping Prescription for the treatment of insomnia of the deficiency type. 120 cases conformed to the diagnostic criteria of the Chinese Classification of Mental Disorders-Version 3 (CCMD-3) and were
Yohei Otsuji et al.
Therapeutic drug monitoring, 24(3), 375-378 (2002-05-22)
To examine the involvement of cytochrome P450 3A4 in the metabolism of estazolam, the effect of itraconazole, a potent inhibitor of this enzyme, on the single oral dose pharmacokinetics and pharmacodynamics of estazolam was studied in a double-blind randomized crossover
M Miura et al.
Xenobiotica; the fate of foreign compounds in biological systems, 35(5), 455-465 (2005-07-14)
To predict drug interactions with estazolam, the biotransformation of estazolam to its major hydoxylated metabolite, 4-hydroxyestazolam was studied in vitro using pooled human liver microsomes and individual expressed human cytochrome P450 (CYP) enzymes. Estazolam was metabolized to 4-hydroxyestazolam according to
Jiu-xi Yuan et al.
Fa yi xue za zhi, 27(2), 117-119 (2011-05-25)
To investigate the stability of estazolam in biological samples preserved in formaldehyde solution. The dog was given intragastric administration of estazolam with a dose of 37.6 mg/kg and killed 2 h later. Heart, liver, kidney and brain of the dog
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持